Reuters
Bristol Myers 1st-quarter sales up on Eliquis, Opdivo
Drugmaker Bristol Myers Squibb posted slightly better-than-expected first-quarter earnings on Friday on growth of sales of its blood thinner Eliquis and cancer drug Opdivo, but said it no longer expects sales growth in 2022 due to stiff generic competition overseas for blood cancer drug Revlimid. The first-quarter dropoff in sales of Revlimid, which lost some patent protection this year, was not as sharp as expected. Still, Bristol Myers cut its full-year sales forecast for Revlimid by $500 million, to $9 billion to $9.5 billion.
